Dec. 1, 2010, 8:33 AM
Specialty pharmaceutical firm Eurand (EURX) agrees to be bought for $12/share in cash by Axcan holdings, a pharma firm focused on gastrointestinal disorders. The $583M deal is a 9% premium to Eurand's close yesterday. (PR)| Dec. 1, 2010, 8:33 AM
Currently, there's no company description for EURX.
Country: United States
Other News & PR